Status:
COMPLETED
A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Advanced Malignancy
Eligibility:
All Genders
21+ years
Brief Summary
The well-established role of vascular endothelial growth factor (VEGF) in carcinogenesis and tumor angiogenesis has led to the development of agents that target this pathway. Anti-VEGF agents the VEGF...
Eligibility Criteria
Inclusion
- Eligibility
- Patients who are receiving single agent anti-VEGF therapy
- Signed written informed consent
- Patients with measurable pulmonary malignancy (primary or metastatic) as determined by RECIST will undergo assessment of pulmonary function
- Patients with a known allergy to intravenous contrast used in fluorescein and indocyanine green angiography will be exempt from these investigations but will undergo other study assessments
Exclusion
- None
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00978926
Start Date
September 1 2009
Last Update
April 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore, 119074